{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:26:24Z","timestamp":1782491184474,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["IN-FR-980-6333"],"award-info":[{"award-number":["IN-FR-980-6333"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"DOI":"10.1186\/s12889-025-24083-3","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:44:46Z","timestamp":1759232686000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Screening tests for hepatitis B, C and D in metropolitan France from 2016 to 2022: a map based on the National Health Data System with a focus on HDV hepatitis"],"prefix":"10.1186","volume":"25","author":[{"given":"C\u00e9line","family":"Rigaud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Loustaud-Ratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"24083_CR1","unstructured":"Global HIV, Hepatitis and STIs Programmes (HHS),, Health Product Policy and Standards (HPS). Global hepatitis report 2024: action for access in low- and middle-income countries. World Health Organization. 2024. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240091672."},{"key":"24083_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jhep.2020.04.008","volume":"73","author":"AJ Stockdale","year":"2020","unstructured":"Stockdale AJ, Kreuels B, Henrion MYR, Giorgi E, Kyomuhangi I, de Martel C, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523\u201332.","journal-title":"J Hepatol"},{"key":"24083_CR3","first-page":"347","volume":"19\u201320","author":"E Gordien","year":"2015","unstructured":"Gordien E. The hepatitis delta virus infection: recent data in France. Bull Epidemiolog Hebdomadaire. 2015;19\u201320:347\u201352.","journal-title":"Bull Epidemiolog Hebdomadaire"},{"key":"24083_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.jhep.2023.10.043","volume":"80","author":"Polaris Observatory Collaborators","year":"2024","unstructured":"Polaris Observatory Collaborators. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. J Hepatol. 2024;80:232\u201342.","journal-title":"J Hepatol"},{"key":"24083_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/v16050792","volume":"16","author":"C Brouard","year":"2024","unstructured":"Brouard C, Schwager M, Expert A, Drewniak N, Laporal S, De Lagasnerie G, et al. Impact of public policy and COVID-19 pandemic on hepatitis C testing and treatment in France, 2014\u20132021. Viruses. 2024;16:792.","journal-title":"Viruses"},{"key":"24083_CR6","first-page":"276","volume":"15\u201316","author":"C Brouard","year":"2023","unstructured":"Brouard C, Laporal S, Cazein F, Saboni L, Bruyand M, Lot F. D\u00e9pistage des h\u00e9patites B ET C EN 2021 En France, Enqu\u00eate Labohep \/ Hepatitis B And C Testing In 2021 In France. LABOHEP SURVEY Bull Epidemiolog Hebdomadaire. 2023;15\u201316:276\u201386.","journal-title":"LABOHEP SURVEY Bull Epidemiolog Hebdomadaire"},{"key":"24083_CR7","unstructured":"Tamandjou C. D\u00e9pistage et diagnostic des h\u00e9patites B et C en CeGIDD en 2022, surveillance SurCeGIDD \/ Screening and diagnosis of hepatitis B and C in French STI clinics (CeGIDD) in 2022, SurCeGIDD surveillance."},{"key":"24083_CR8","doi-asserted-by":"publisher","first-page":"e00049","DOI":"10.7554\/eLife.00049","volume":"1","author":"H Yan","year":"2012","unstructured":"Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1:e00049.","journal-title":"Elife"},{"key":"24083_CR9","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jhep.2020.06.038","volume":"73","author":"D Roulot","year":"2020","unstructured":"Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, et al. Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol. 2020;73:1046\u201362.","journal-title":"J Hepatol"},{"key":"24083_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcv.2013.11.016","volume":"59","author":"A Servant-Delmas","year":"2014","unstructured":"Servant-Delmas A, Le Gal F, Gallian P, Gordien E, Laperche S. Increasing prevalence of HDV\/HBV infection over 15 years in France. J Clin Virol. 2014;59:126\u20138.","journal-title":"J Clin Virol"},{"key":"24083_CR11","doi-asserted-by":"publisher","first-page":"100593","DOI":"10.1016\/j.jhepr.2022.100593","volume":"4","author":"S Chevaliez","year":"2022","unstructured":"Chevaliez S, Roudot-Thoraval F, Brouard C, Gordien E, Zoulim F, Brichler S, et al. Clinical and virological features of chronic hepatitis B in the French national surveillance program, 2008\u20132012: a cross-sectional study. JHEP Rep. 2022;4:100593.","journal-title":"JHEP Rep"},{"key":"24083_CR12","unstructured":"HAS. Haute Autorit\u00e9 de sant\u00e9. Prise en charge des personnes infect\u00e9es par les virus de l\u2019h\u00e9patite B, C ou D. 2024;Available from: https:\/\/www.has-sante.fr\/jcms\/p_3324682\/fr\/prise-en-charge-des-personnes-infectees-par-les-virus-de-l-hepatite-b-c-ou-d#toc_1_4_1."},{"key":"24083_CR13","doi-asserted-by":"publisher","unstructured":"Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, Lemoine M, et al. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018. Cit\u00e9 2025 mai 26.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"24083_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa2213429","volume":"389","author":"H Wedemeyer","year":"2023","unstructured":"Wedemeyer H, Aleman S, Brunetto MR, Blank A, Andreone P, Bogomolov P, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389:22\u201332.","journal-title":"N Engl J Med"},{"issue":"Suppl 4","key":"24083_CR15","doi-asserted-by":"publisher","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","volume":"65","author":"P Tuppin","year":"2017","unstructured":"Tuppin P, Rudant J, Constantinou P, Gastaldi-M\u00e9nager C, Rachas A, de Roquefeuil L, et al. Value of a national administrative database to guide public decisions: From the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65(Suppl 4):S149\u201367.","journal-title":"Rev Epidemiol Sante Publique"},{"key":"24083_CR16","unstructured":"Pioche C, L\u00e9on L, Larsen C, Lot F, Pillonel J, Brouard C. Hepatitis B AND C Screening In France In 2013, Labohep Study. 7."},{"key":"24083_CR17","unstructured":"Enqu\u00eate nationale p\u00e9rinatale Rapport 2016 [Internet]. 2017;Available from: https:\/\/enp.inserm.fr\/wp-content\/uploads\/2020\/05\/ENP2016_Rapport.pdf"},{"key":"24083_CR18","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1097\/QAD.0000000000003024","volume":"35","author":"JM Ramos-Rincon","year":"2021","unstructured":"Ramos-Rincon JM, Pinargote H, Ramos-Belinch\u00f3n C, de Mendoza C, Aguilera A, Soriano V. Hepatitis delta in patients hospitalized in Spain (1997\u20132018). AIDS. 2021;35:2311\u20138.","journal-title":"AIDS"},{"key":"24083_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.12.044","author":"E Degasperi","year":"2025","unstructured":"Degasperi E, Anolli MP, Jachs M, Reiberger T, De Ledinghen V, Metivier S, et al. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis. J Hepatol. 2025. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.044.","journal-title":"J Hepatol"},{"key":"24083_CR20","first-page":"311","volume":"15\u201316","author":"C Tamandjou","year":"2023","unstructured":"Tamandjou C, Laporal S, Lot F, Brouard C. Donn\u00e9es \u00e9pid\u00e9miologiques r\u00e9centes sur les h\u00e9patites C, B ET DELTA \/ updated epidemiological data on hepatitis C B AND DELTA. Bull Epidemiolog Hebdomadaire. 2023;15\u201316:311\u20137.","journal-title":"Bull Epidemiolog Hebdomadaire"},{"key":"24083_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/jvh.13798","volume":"30","author":"M Debette-Gratien","year":"2023","unstructured":"Debette-Gratien M, Fran\u00e7ois S, Chevalier C, Alain S, Carrier P, Rigaud C, et al. Towards hepatitis C elimination in France: Scanvir, an effective model to test and treat drug users on dedicated days. J Viral Hepat. 2023;30:355\u201361.","journal-title":"J Viral Hepat"},{"key":"24083_CR22","unstructured":"EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol 2023;79:433\u201160."},{"key":"24083_CR23","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.jhep.2023.02.041","volume":"79","author":"HA Razavi","year":"2023","unstructured":"Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV\/HDV-prevalence countries. J Hepatol. 2023;79:576\u201380.","journal-title":"J Hepatol"},{"key":"24083_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1111\/liv.15746","volume":"44","author":"V Cossiga","year":"2024","unstructured":"Cossiga V, Brusa S, Montalti R, De Conte A, Jannuzzi G, Ranieri L, et al. Anti-HDV reflex testing in HBsAg-positive subjects: an efficacious strategy to identify HDV infection. Liver Int. 2024;44:148\u201354.","journal-title":"Liver Int"},{"key":"24083_CR25","doi-asserted-by":"publisher","first-page":"100813","DOI":"10.1016\/j.jhepr.2023.100813","volume":"6","author":"MN Hilleret","year":"2024","unstructured":"Hilleret MN, Flacher E, Germi R, Lupo J, Larrat S. Reflex testing automatization for HBsAg carriers: a novel era for hepatitis delta management. JHEP Rep. 2024;6:100813.","journal-title":"JHEP Rep"},{"key":"24083_CR26","doi-asserted-by":"publisher","first-page":"25921","DOI":"10.1038\/s41598-024-77737-4","volume":"14","author":"J Bernhard","year":"2024","unstructured":"Bernhard J, Schwarz M, Balcar L, Hofer B, Dominik N, Strassl R, et al. Reflex testing for anti-HDV in HBsAg-positive patients offers high diagnostic yield in a large Central European tertiary care center. Sci Rep. 2024;14:25921.","journal-title":"Sci Rep"},{"key":"24083_CR27","doi-asserted-by":"publisher","first-page":"100547","DOI":"10.1016\/j.jhepr.2022.100547","volume":"4","author":"A Palom","year":"2022","unstructured":"Palom A, Rando-Segura A, Vico J, Pac\u00edn B, Vargas E, Barreira-D\u00edaz A, et al. Implementation of anti-HDV reflex testing among HBsAg-positive individuals increases testing for hepatitis D. JHEP Rep. 2022;4:100547.","journal-title":"JHEP Rep"},{"key":"24083_CR28","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1111\/liv.15776","volume":"43","author":"M Buti","year":"2023","unstructured":"Buti M, Dom\u00ednguez-Hern\u00e1ndez R, Palom A, Esteban R, Casado M\u00c1. Impact of hepatitis D reflex testing on the future disease burden: a modelling analysis. Liver Int. 2023;43:2611\u20134.","journal-title":"Liver Int"},{"key":"24083_CR29","doi-asserted-by":"publisher","first-page":"300","DOI":"10.4254\/wjh.v16.i3.300","volume":"16","author":"Z Abbas","year":"2024","unstructured":"Abbas Z, Abbas M. Is there a need for universal double reflex testing of HBsAg-positive individuals for hepatitis D infection? World J Hepatol. 2024;16:300\u20133.","journal-title":"World J Hepatol"},{"key":"24083_CR30","doi-asserted-by":"publisher","first-page":"114039","DOI":"10.1016\/j.jviromet.2020.114039","volume":"289","author":"J Mart\u00ednez-Campreci\u00f3s","year":"2021","unstructured":"Mart\u00ednez-Campreci\u00f3s J, Rando-Segura A, Buti M, Rodrigo-Vel\u00e1squez F, Riveiro-Barciela M, Barreira-D\u00edaz A, et al. Reflex viral load testing in dried blood spots generated by plasma separation card allows the screening and diagnosis of chronic viral hepatitis. J Virol Methods. 2021;289:114039.","journal-title":"J Virol Methods"},{"key":"24083_CR31","unstructured":"Delagarde V, Gerber A, Dziri S, Roulot D, Gordien E, Le Gal F, et al. Improving access to HDV Testing using dry blood spots. 1230C. 2023;Available from: https:\/\/www.aasld.org\/sites\/default\/files\/2023-10\/the_liver_meeting_boston_massachusetts_nov1_0.pdf."},{"key":"24083_CR32","unstructured":"Pioche C, L\u00e9on L, Vaux S, Brouard C, Lot F. D\u00e9pistage des h\u00e9patites B ET C EN FRANCE EN 2016, Nouvelle \u00e9dition de l\u2019enqu\u00eate labohep \/ hepatitis B and C screening In France In 2016. THE NEW EDITION OF THE LABOHEP STUDY. 2018;188\u201195."},{"key":"24083_CR33","unstructured":"Journal Officiel. D\u00e9cret n\u00b0 2023\u2013700 du 31 juillet 2023 relatif \u00e0 la transmission obligatoire de donn\u00e9es individuelles \u00e0 l\u2019autorit\u00e9 sanitaire et \u00e0 la cr\u00e9ation du traitement de donn\u00e9es \u00e0 caract\u00e8re personnel LABO\u00e9-SI. 2023. Available from: https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000047911698."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24083-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-025-24083-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-025-24083-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T11:44:47Z","timestamp":1759232687000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-025-24083-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24083"],"URL":"https:\/\/doi.org\/10.1186\/s12889-025-24083-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5662958\/v1","asserted-by":"object"}]},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"17 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study uses data from the SNDS. Respect for individual rights is the responsibility of the national health insurance fund. Under French regulations, all individuals have the right to object to their health data being used for research purposes by informing the director of their health insurance fund. Thus, under article R1461-9 of the French Public Health Code, consent to participate is not required. The Limoges University Hospital has permanent access to the SNDS according to the decree of the Official Journal No. 0150 of June 30, 2021. Access and use of these data is performed in compliance with the SNDS security framework, and the personnel concerned have receiveed mandatory training and have been authorized to extract SNDS data. This project was evaluated and approved by the Limoges University Hospital and then registered in the Health Data Hub directory (No. F20231116101028).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participation"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3169"}}